All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | APR 2025 | APR 2024 ~1.3:1 split | APR 2023 | APR 2022 |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | – | – | $50 | – | – |
| General & Administrative | – | $116 | $54 | $31 | $26 |
| Research & Development | – | $72 | $86 | $80 | $70 |
| Total Operating Expenses | – | $188 | $140 | $111 | $97 |
| Operating Income | – | -$188 | -$140 | -$111 | -$97 |
| Non-Operating | |||||
| Net Interest Expense | – | $1 | $4 | $2 | $1 |
| Other Non-Operating Income (Expense) | – | $7 | $10 | $16 | $13 |
| EBT (Earnings Before Tax) | – | -$180 | -$127 | -$93 | -$82 |
| Income Tax Expense | – | $3 | $0 | $0 | $0 |
| Net Income | |||||
| Net Income | – | -$183 | -$127 | -$93 | -$82 |
| Per Share Data | |||||
| Revenue Per Share | – | – | $1.36 | – | – |
| EPS (Basic) | – | -$3.69 | -$3.44 | -$3.33 | -$3.36 |
| EPS (Diluted) | – | -$3.69 | -$3.44 | -$3.33 | -$3.36 |
| Weighted Avg Shares (Basic) | 53.9M | 49.7M | 36.8M | 27.9M | 24.5M |
| Weighted Avg Shares (Diluted) | 53.9M | 49.7M | 36.8M | 27.9M | 24.5M |
| Shares Outstanding | 53.9M | 49.7M | 36.8M | 27.9M | 24.5M |
KalVista Pharmaceuticals (KALV) financials: revenue, profit and margins
KalVista Pharmaceuticals (KALV) generated about n/a in revenue and -$191 million in net income over the trailing twelve months, growing at roughly 87.9% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is KalVista Pharmaceuticals profitable?+
KalVista Pharmaceuticals reported about -$191 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is KalVista Pharmaceuticals growing?+
KalVista Pharmaceuticals's revenue has compounded at roughly 87.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside KALV's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with KALV
Held by ETFs
KALV is in 3 US ETFs. The largest of them, with KALV's weight in each:
Spot a number that looks wrong? Check it in KALV's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KALV
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.